Robert's Feed
Oct 28, 2015
via Breakingviews

No simple cures for Gilead and Apple valuations

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

There are no simple cures for the valuations of Gilead Sciences and Apple. Like the $670 billion iPhone maker, the $158 billion biotech is the leader in its industry and churns out hefty profit. Yet its stock trades at a big price-to-earnings discount to the broader market. Investor impatience for astonishing new products – and fears that neither company will find them – borders on the irrational.

Oct 27, 2015
via Breakingviews

Apple: a tech company with Chinese characteristics

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Apple is becoming a tech company with Chinese characteristics. About 24 percent of the $51.5 billion of sales booked in its latest quarter – and two-thirds of revenue growth over the last year – came from China. Apple’s new iPhone installment plan could bump this up even further. Chief Executive Tim Cook’s bet on the Middle Kingdom is yielding impressive dividends, but carries existential political risks for the $675 billion company.

Oct 27, 2015
via Breakingviews

Apple: a tech company with Chinese characteristics

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Apple is becoming a tech company with Chinese characteristics. About 24 percent of the $51.5 billion of sales booked in its latest quarter – and two-thirds of revenue growth over the last year – came from China. Apple’s new iPhone installment plan could bump this up even further. Chief Executive Tim Cook’s bet on the Middle Kingdom is yielding impressive dividends, but carries existential political risks for the $675 billion company.

Oct 26, 2015
via Breakingviews

Valeant’s clarification efforts further tangle web

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Valeant Pharmaceuticals further tangled its web. The acquisitive $39 billion company tried on Monday to spell out its ties to drug distributors. Analysts didn’t ask – and a 90-page presentation and call with investors didn’t answer – why it obscured the dealings in the first place. The messy details also only go to confirm some fears about Valeant.

Oct 23, 2015
via Breakingviews

Twitter CEO’s creative giveback is promising start

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The Silicon Valley set typically professes to want to make the world a better place. The platitude is often accompanied by rich compensation packages. That’s why the creative giveback by Twitter boss Jack Dorsey stands out as a promising start for his second reign as chief executive.

Oct 23, 2015
via Breakingviews

Twitter CEO’s creative giveback is promising start

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The Silicon Valley set typically professes to want to make the world a better place. The platitude is often accompanied by rich compensation packages. That’s why the creative giveback by Twitter boss Jack Dorsey stands out as a promising start for his second reign as chief executive.

Oct 22, 2015
via Breakingviews

Google and Amazon grapple happily with maturity

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Alphabet and Amazon are grappling happily with maturity. The $450 billion holding company for Google is returning lots more money to shareholders. The $260 billion internet mega-retailer delivered profits. Both operations are growing so fast, and throwing off so much cash, that they can act as responsible stewards of capital while still chasing the next big thing.

Oct 22, 2015
via Breakingviews

Google and Amazon grapple happily with maturity

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Alphabet and Amazon are grappling happily with maturity. The $450 billion holding company for Google is returning lots more money to shareholders. The $260 billion internet mega-retailer delivered profits. Both operations are growing so fast, and throwing off so much cash, that they can act as responsible stewards of capital while still chasing the next big thing.

Oct 22, 2015
via Breakingviews

Valeant sets tone for post-M&A accounting scrutiny

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Valeant Pharmaceuticals sets the tone for intensifying accounting scrutiny once merger activity slows. The drugmaker’s stock ended Wednesday down 19 percent after a short-seller and others questioned its bookkeeping and relationships with other companies. The $40 billion serial acquirer’s history may make it an obvious target, but as growth and mergers slow a renewed investor focus on companies’ figures is a logical shift.

Oct 22, 2015
via Breakingviews

Valeant sets tone for post-M&A accounting scrutiny

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Valeant Pharmaceuticals sets the tone for intensifying accounting scrutiny once merger activity slows. The drugmaker’s stock ended Wednesday down 19 percent after a short-seller and others questioned its bookkeeping and relationships with other companies. The $40 billion serial acquirer’s history may make it an obvious target, but as growth and mergers slow a renewed investor focus on companies’ figures is a logical shift.

    • About Robert

      "Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University."
    • Follow Robert